2020
Choice of imaging modality for pre-treatment staging of head and neck cancer impacts TNM staging
Mur T, Sambhu KM, Mahajan A, Payabvash S, Fernandez J, Edwards HA. Choice of imaging modality for pre-treatment staging of head and neck cancer impacts TNM staging. American Journal Of Otolaryngology 2020, 41: 102662. PMID: 32858370, DOI: 10.1016/j.amjoto.2020.102662.Peer-Reviewed Original ResearchConceptsPET/CTLow-dose nonenhanced CTDistant metastasisChest CTNeck cancerNonenhanced CTF-fluorodeoxyglucose positron emission tomographyF-FDG PET/CTDiagnostic chest CTDistant metastatic diseaseInitiation of therapyRetrospective cohort studyPre-treatment stagingTertiary care settingSignificant differencesPositron emission tomographyMetastatic diseaseCohort studyOncologic treatmentTNM stagingInaccurate stagingNeck radiologistsCare settingsSingle patientPatients
2019
Multi-Institutional Validation of Deep Learning for Pretreatment Identification of Extranodal Extension in Head and Neck Squamous Cell Carcinoma.
Kann BH, Hicks DF, Payabvash S, Mahajan A, Du J, Gupta V, Park HS, Yu JB, Yarbrough WG, Burtness BA, Husain ZA, Aneja S. Multi-Institutional Validation of Deep Learning for Pretreatment Identification of Extranodal Extension in Head and Neck Squamous Cell Carcinoma. Journal Of Clinical Oncology 2019, 38: 1304-1311. PMID: 31815574, DOI: 10.1200/jco.19.02031.Peer-Reviewed Original ResearchConceptsNeck squamous cell carcinomaExtranodal extensionSquamous cell carcinomaLymph nodesCell carcinomaContrast-enhanced CT scanDiagnostic abilityBoard-certified neuroradiologistsTreatment escalationCancer Genome AtlasPathologic confirmationPretreatment identificationDiagnostic challengeExternal validation data setsPathology resultsPretreatment imagingPoor prognosticatorClinical utilityCT scanPatientsClinical decisionHNSCCDiagnostic accuracyInstitutional ValidationGenome Atlas
2018
Incidence of radiographically occult nodal metastases in HPV+ oropharyngeal carcinoma: Implications for reducing elective nodal coverage
Loganadane G, Kelly JR, Lee NC, Kann BH, Mahajan A, Hansen JE, Belkacémi Y, Yarbrough W, Husain ZA. Incidence of radiographically occult nodal metastases in HPV+ oropharyngeal carcinoma: Implications for reducing elective nodal coverage. Practical Radiation Oncology 2018, 8: 397-403. PMID: 29730282, DOI: 10.1016/j.prro.2018.03.009.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overCarcinoma, Squamous CellFemaleFollow-Up StudiesHumansImage Processing, Computer-AssistedLymphatic MetastasisMaleMiddle AgedNeoplasm StagingOropharyngeal NeoplasmsPapillomaviridaePapillomavirus InfectionsPositron Emission Tomography Computed TomographyPrognosisRadiotherapy DosageRadiotherapy Planning, Computer-AssistedRadiotherapy, Intensity-ModulatedRetrospective StudiesConceptsRadiation field designPreoperative imagingPathologic involvementN stageOropharyngeal squamous cell carcinomaElective nodal coverageLevel II diseasePercent of patientsPositive lymph nodesOccult nodal metastasisClinical N stageRadiation therapy doseRecords of patientsNodal levelPathologic N stageSquamous cell carcinomaHuman papilloma virusTreatment deescalationNeoadjuvant therapyNodal diseaseNeck dissectionNodal involvementOropharyngeal carcinomaProspective trialSystemic agents
2016
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial
Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M, Tsiouris AJ, Cohen J, Vortmeyer A, Jilaveanu L, Yu J, Hegde U, Speaker S, Madura M, Ralabate A, Rivera A, Rowen E, Gerrish H, Yao X, Chiang V, Kluger HM. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. The Lancet Oncology 2016, 17: 976-983. PMID: 27267608, PMCID: PMC5526047, DOI: 10.1016/s1470-2045(16)30053-5.Peer-Reviewed Original ResearchConceptsProgressive brain metastasesUntreated brain metastasesBrain metastasis responseYale Cancer CenterBrain metastasesPhase 2 trialCell lung cancerAdverse eventsMetastasis responseCancer CenterLung cancerMelanoma cohortGrade 3 colitisGrade 3 fatigueGrade 3 pneumonitisPD-1 axisAcute kidney injuryNeurological adverse eventsPD-1 inhibitorsAcceptable safety profilePD-L1 expressionSystemic immunotherapyKidney injuryPrimary endpointNSCLC cohort
2011
Ocular Neoplastic Disease
Mahajan A, Crum A, Johnson MH, Materin MA. Ocular Neoplastic Disease. Seminars In Ultrasound CT And MRI 2011, 32: 28-37. PMID: 21277489, DOI: 10.1053/j.sult.2010.12.001.Peer-Reviewed Original ResearchConceptsClinical ophthalmologic examinationOphthalmologic examinationScan ultrasoundCommon imaging appearancesMagnetic resonance imagingOcular metastasisOcular oncologistRetinal detachmentVisual disturbancesFluorescein angiographyMalignant neoplasmsMass lesionImaging appearancesTumor stagingVision lossDiagnostic findingsOcular neoplasmsUveal melanomaNeoplastic diseaseResonance imagingTreatment assessmentNeoplasmsStagingUltrasoundExamination